Roche Names O’Day Pharma Head as Soriot Becomes AstraZeneca CEO

Roche Holding AG (ROG) named Daniel O’Day head of its pharmaceuticals division to succeed Pascal Soriot, who is leaving the Swiss drugmaker to become chief executive officer of AstraZeneca Plc. (AZN)

O’Day will begin the position Sept. 1, the Basel, Switzerland-based company said today in an e-mailed statement. Roland Diggelmann will succeed O’Day as head of diagnostics, Roche said.

Diggelmann is currently head of the Asia-Pacific region for the diagnostics unit.

To contact the reporter on this story: Thomas Mulier in Geneva at

To contact the editor responsible for this story: David Risser at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.